The presence of sleep disorders in the earliest stages of Parkinson’s disease correlated with blood levels of neurofilament light chain (NfL), a biomarker of neurodegeneration, in a study. “This finding underscores the potential of sleep disorders as a robust clinical indicator of neuronal degeneration, closely linked with PD [Parkinson’s…
News
Enhancing mechanisms associated with the degradation of misfolded proteins at the proteasome, that is, cellular structures where these proteins are degraded, may be a new therapeutic target for neurodegenerative diseases, including Parkinson’s disease. That’s according to a new study in fruit flies, where researchers found that the ZIP7 protein,…
Six years before world champion boxer Muhammad Ali was diagnosed with Parkinson’s disease, his young daughter noticed he was slurring his speech. It was around the time of Ali’s heavyweight championship fight against Leon Spinks. “People thought he was ‘punch drunk’ from boxing,” the daughter, Maryum “May May” Ali,…
The first 25 patients have been enrolled in a Phase 3 trial that’s testing the light-based, at-home therapy device called Celeste for treating Parkinson’s disease, its developer PhotoPharmics has announced. The “Celeste Light for PD Trial” is evaluating the device’s safety and effectiveness at easing both motor…
A newly developed molecule showed an ability in lab studies to activate antioxidant responses in brain cells by altering how two proteins, believed to be involved in the development of Parkinson’s disease and other neurodegenerative conditions, interact. The small molecule, known as a protein-like polymer, is designed to bind to…
People with Parkinson’s disease who have clinically significant anxiety tend to walk more slowly and with shorter steps than people with the disease who don’t have anxiety. That’s according to the study, “The impact of anxiety on gait impairments in Parkinson’s disease: insights from sensor-based gait analysis,” which…
Topline efficacy data from a Phase 3 clinical trial evaluating the oral therapy buntanetap for early-stage Parkinson’s disease is now expected in June, Annovis Bio, the therapy’s developer, has disclosed. While Annovis originally planned to share its early findings at the beginning of this year, the company faced…
Tiny bubbles containing a flaky form of phosphorus, called black phosphorus, delivered to the brain may help to control overactive microglia — the brain’s resident immune cells — that drive the inflammation damaging to nerve cells in Parkinson’s disease, scientists in China report. In a study in a rat…
There were more cases of Parkinson’s disease and cancer than expected among attorneys who worked near a now-closed dry cleaner in Rochester, New York that leaked trichloroethylene (TCE) and other dry cleaning solvents into the soil, a study finds. While they failed to reach statistical significance, the findings add…
Deficits in emotional processing, rather than impaired ability to simulate facial expressions, likely explain problems Parkinson’s disease patients encounter when trying to recognize emotions on human faces, a study suggests. Researchers asked patients and healthy individuals to recognize different, non-emotional facial expressions on avatars, either static or moving. No…
Recent Posts
- Light therapy device seen to brighten life quality for those with Parkinson’s
- When early memories of Parkinson’s came full circle
- FDA grants advanced therapy status to Parkinson’s cell treatment
- Experimental drug BT-267 shows promise in Parkinson’s study
- Saying goodbye to my doctors leaves me sad, but grateful